



Well-differentiated liver cancers reveal the potential link between ACE2 dysfunction and metabolic breakdown

Lise Desquilles, Luis Cano, Gevorg Ghukasyan, Nicolas Mouchet, Clemence Landreau, Anne Corlu, Bruno Clement, Bruno Turlin, Romain Desert, Orlando Musso

► To cite this version:

Lise Desquilles, Luis Cano, Gevorg Ghukasyan, Nicolas Mouchet, Clemence Landreau, et al.. Well-differentiated liver cancers reveal the potential link between ACE2 dysfunction and metabolic breakdown. Scientific Reports, 2022, 12 (1), pp.1859. 10.1038/s41598-021-03710-0 . hal-03592989

HAL Id: hal-03592989

<https://hal.science/hal-03592989>

Submitted on 6 May 2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution 4.0 International License



OPEN

Well-differentiated liver cancers reveal the potential link between ACE2 dysfunction and metabolic breakdown

Lise Desquilles¹, Luis Cano¹, Gevorg Ghukasyan², Nicolas Mouchet², Clémence Landreau¹, Anne Corlu¹, Bruno Clément¹, Bruno Turlin¹, Romain Désert¹ & Orlando Musso^{1✉}

Angiotensin-converting enzyme 2 (*ACE2*) is the receptor of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) causing Coronavirus disease 2019 (COVID-19). Transmembrane serine protease 2 (*TMPRSS2*) is a coreceptor. Abnormal hepatic function in COVID-19 suggests specific or bystander liver disease. Because liver cancer cells express the ACE2 viral receptor, they are widely used as models of SARS-CoV-2 infection in vitro. Therefore, the purpose of this study was to analyze ACE2 and TMPRSS2 expression and localization in human liver cancers and in non-tumor livers. We studied ACE2 and TMPRSS2 in transcriptomic datasets totaling 1503 liver cancers, followed by high-resolution confocal multiplex immunohistochemistry and quantitative image analysis of a 41-HCC tissue microarray. In cancers, we detected ACE2 and TMPRSS2 at the biliary pole of tumor hepatocytes. In whole mount sections of five normal liver samples, we identified ACE2 in hepatocyte's bile canaliculi, biliary epithelium, sinusoidal and capillary endothelial cells. Tumors carrying mutated β -catenin showed ACE2 DNA hypomethylation and higher mRNA and protein expression, consistently with predicted β -catenin response sites in the ACE2 promoter. Finally, ACE2 and TMPRSS2 co-expression networks highlighted hepatocyte-specific functions, oxidative stress and inflammation, suggesting a link between inflammation, ACE2 dysfunction and metabolic breakdown.

Abbreviations

ACE2	Angiotensin-converting enzyme 2
Ang	Angiotensin
CLEC4M	C-Type Lectin Domain Family 4 Member M
DPP4	Dipeptidyl Peptidase 4
COVID-19	Coronavirus disease 2019
CTNNB1	β -Catenin
HCC	Hepatocellular carcinoma
LSECs, MERS-CoV	Middle East Respiratory Syndrome Coronavirus
SARS-CoV-2	Severe Acute Respiratory Syndrome Coronavirus 2
TCGA	The Cancer Genome Atlas
TMPRSS2	Transmembrane serine protease 2

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) causes the Coronavirus disease 2019 (COVID-19)^{1–3}. SARS-CoV-2 is an enveloped RNA betacoronavirus phylogenetically similar to SARS-CoV and the Middle East Respiratory Syndrome Coronavirus (MERS-CoV). Although ~80% of SARS-CoV-2-infected individuals develop asymptomatic self-limited upper airway forms of COVID-19, approximately 15% need hospitalization and 5% develop severe disease with acute respiratory distress syndrome, immune dysregulation and a “cytokine storm” with disseminated intravascular coagulation^{1,3,4}. Approximately 50% of hospitalized patients present comorbidities: hypertension, type-2 diabetes and coronary heart disease^{1–3,5,6}.

The baseline prevalence of chronic liver disease in COVID-19 was about three percent in two meta-analyses assembling 3301 patients^{7,8}, but the mean prevalence of COVID-19 related liver dysfunction was about 20%

¹INSERM, INRAE, University of Rennes, Nutrition Metabolisms and Cancer, Rennes, France. ²University of Rennes, CNRS, INSERM, UMS Biosit, Core Facility H2P2, 35000 Rennes, France. ✉email: orlando.musso@inserm.fr

(range 14–53%)^{1,6–9}. Liver dysfunction correlates with the extent of pulmonary lesions¹⁰. Patients with hepatocyte-type dysfunction at admission are at higher risk of progressing to severe COVID-19¹¹. After admission, antiviral drugs such as lopinavir and ritonavir are risk factors for liver damage¹¹. Autopsies suggested that SARS-CoV-2 infects and replicates within hepatocytes in severe COVID-19 cases^{12–14} and SARS-CoV-2 RNA has been detected in the respiratory epithelium, kidney, liver, heart, brain, blood and stools in severe COVID-19 cases^{15,16}. In addition, crown-like viral particles with complete envelope and typical spikes have been observed in lung, kidney^{16,17} and in hepatocytes¹⁴ suggesting multiorgan targeting of COVID-19.

Cell entry of SARS-CoV and SARS-CoV-2 depends on the binding of the viral spike (S) protein to the Angiotensin-converting enzyme 2 (ACE2) and on the serine protease TMPRSS2 for S protein fusion^{18,19}. The rate of SARS-CoV-2 infection correlates with cell surface ACE2 expression^{18,19}. Importantly, Huh-7^{18,20} human hepatocellular carcinoma (HCC) and HepG2 hepatoblastoma²⁰ cells are widely used models of SARS-CoV-2 infection because they express cell surface ACE2 and can be infected at high titers.

As liver cancer cells are in vitro models for the study of SARS-CoV-2 entry and cytopathic effects, we extensively studied mRNA, protein expression and localization of the viral receptors ACE2 and TMPRSS2 in human HCCs. This characterization will be useful to design in vitro studies on virus entry, replication and metabolic alterations in liver cells.

Results

Higher expression of *ACE2* and *TMPRSS2* mRNAs in HCCs with mutated β -catenin. We first searched for relationships of *ACE2* and *TMPRSS2* mRNA expression levels with HCC aggressiveness. To this end, overall and disease-free survival analyses were carried out in the TCGA dataset ($n = 370$). After applying the exclusion criteria described in Supplementary Fig. 1a, the survival dataset consisted of 256 patients. In consistency with previous reports^{21–23}, higher *ACE2* and *TMPRSS2* mRNA expression were associated with better overall and disease-free survival (Supplementary Fig. 1b and 2a). *ACE2* and *TMPRSS2* mRNAs were also detected in 47 non-tumor livers in the TCGA dataset. Whereas *ACE2* mRNA expression was 1.7-fold higher in non-tumors livers than in HCCs, *TMPRSS2* expression did not differ between both groups (Supplementary Fig. 2b).

In HCCs, the expression of genes associated with relatively good prognosis is frequently preserved in well-differentiated tumors because they maintain the phenotype of adult hepatocytes^{24,25}. To verify if this applied to *ACE2* and *TMPRSS2*, we measured their expression levels in HCCs classified according to their likeness to normal hepatocytes. Thus classified, HCCs are divided into two major classes, namely “low-proliferation” and “high-proliferation”²⁵. Four HCC subclasses result from the interaction of, on one hand, the metabolic phenotype and, on the other hand, the proliferation/differentiation ratios of tumor cells^{24,26}. Hence, in the “low-proliferation” class of well-to-moderately differentiated HCCs, the periportal-type (PP) and perivenous-type (PV) subclasses refer to the preservation of the metabolic zonation functions of normal hepatocytes^{24,26}. At the opposite end of the spectrum, in the “high-proliferation” class of moderately-to-poorly differentiated HCCs, the extracellular-matrix-type (ECM) and STEM-type subclasses, refer to tumors developing an important stromal and vascular support and expressing cancer stem cell markers^{24,26}. In this context, we found higher *ACE2* mRNA expression in perivenous-type HCCs than in the other subclasses (Fig. 1a; Supplementary Fig. 2c) in both the Desert’s cDNA microarray meta-dataset (1133 HCCs)²⁶ (Fig. 1a) and in the TCGA dataset (370 HCCs) (Supplementary Fig. 2c). Of note, *ACE2* mRNA expression was higher in HCCs expressing previously validated β -catenin pathway activation signatures^{26,27} (Fig. 1b) and in HCCs carrying sequenced β -catenin (*CTNNB1*) activating mutations (Supplementary Fig. 2c). In turn, *TMPRSS2* was expressed at higher levels in periportal-type HCCs (Supplementary Fig. 2c, d), which we previously demonstrated to carry wild-type *CTNNB1* and to belong to the “low-proliferation” class of well-to-moderately differentiated HCCs that preserve the periportal metabolic functions of normal hepatocytes²⁶. The MERS-CoV receptor, *DPP4*, was also related to β -catenin pathway activation (Supplementary Fig. 2e–g). *ACE2* DNA was hypomethylated in tumors carrying *CTNNB1* mutations (Fig. 1c), which is consistent with transcriptional activation the *ACE2* gene. By contrast, *TMPRSS2* was hyper-methylated in HCCs carrying *CTNNB1* mutations (Supplementary Fig. 3a; Supplementary Table 1), which is consistent with transcriptional repression. Neither *ACE2* nor *DPP4* mRNA expression were related *TERT* and *TP53* gene mutations, which are the two most frequent mutations in HCCs (Supplementary Fig. 3c, d). In turn, *TMPRSS2* mRNA levels were higher in HCCs carrying wild-type *TP53* (Supplementary Fig. 3d), which is consistent with the above-described higher expression of *TMPRSS2* in the well-differentiated, non-proliferative class of HCCs, where *TP53* gene mutations are rare^{26,28}. Indeed, *TP53* mutations are most frequent in poorly-differentiated HCCs (S2²⁹, G3³⁰), showing an aggressive, cancer stem cell phenotype^{26,31}.

In line with the higher *ACE2* and *DPP4* mRNA expression in HCCs showing increased β -catenin pathway activation and *CTNNB1* activating mutations, in silico analysis of 5,000 base pairs upstream of the transcription start sites of *ACE2* and *DPP4* DNAs revealed putative T-cell factor 4/LEF-1 consensus transcription factor binding sites, respectively (Fig. 1d; Supplementary Fig. 4a, b).

***ACE2* is predominantly immunodetected in perivenous-type HCCs carrying *CTNNB1* mutations and preserving hepatocyte polarization.** In consistency with the above findings, scoring of immunohistochemical signal for *ACE2* and for the β -catenin target gene *GLUL* (glutamine synthetase) in a tissue microarray of 41 HCCs (Fig. 1e, f; Supplementary Table 5) revealed that the expression of *ACE2* and *GLUL* were correlated (Spearman’s $R = 0.62$; $p < 0.001$; $n = 38$). Sanger sequencing of the mutational hotspot in the 3rd exon of *CTNNB1* revealed that HCCs carrying *CTNNB1* activating mutations expressed 5.1- and 3.3-fold higher levels of *GLUL* and *ACE2* proteins than those carrying wild-type *CTNNB1* (Fig. 1e–h; Supplementary Table 5). To confirm whether tumors expressing the highest levels of *ACE2* protein corresponded to perivenous-type HCCs, we applied our previously described β -catenin pathway activation score²⁶. It results from an equation based on




Figure 1. High *ACE2* levels in well-differentiated, non-proliferative HCCs, with mutated β -catenin (*CTNNB1*) and hypomethylated DNA. (a) and (b) *ACE2* mRNA expression in the Désert's meta-dataset of 1133 HCCs²⁶. (a) HCC subclasses: PP, periportal-type; PV, perivenous-type; ECM, extracellular-matrix-type and STEM, stem-cell-type HCCs. (b) *ACE2* mRNA expression according to β -catenin activation levels, assessed as described²⁶. (c) *ACE2* DNA is hypomethylated in HCCs carrying mutated *CTNNB1* (TCGA dataset). (d) TCF/LEF-1 binding sites, responding to β -catenin transcriptional activation in the proximal *ACE2* DNA sequence upstream the transcription start site, according to the PROMO program (TRANSFAC database). (e) and (f) Immunohistochemical detection (brown signal) of *ACE2* (e) and *GLUL* (glutamine synthetase, (f) in an HCC tissue microarray (TMA). Slides were slightly counterstained with hematoxylin (blue). Three 1-mm in diameter spots were punched from each formalin-fixed paraffin-embedded routine liver tissue block ($n = 41$ HCCs; 2 normal liver controls). Digital slides were acquired with a 20X objective. (g) *ACE2* and *GLUL* immunohistochemical signal scoring in HCCs, according to the tumor's *CTNNB1* mutational status, (MUT) versus wild-type (WT); and β -catenin activation scores, (High) versus (Low), using the median value as a cut-off (High, β -catenin activation score > 4). TMA scores are shown as mean (red bar) \pm 95% confidence intervals (blue bars). Each dot corresponds to the average out of triplicate tissue cores from each HCC. Statistical differences between means calculated with Mann–Whitney *U* test. Tumor numbers for each group are indicated. Only were scored those HCCs for which at least two spots were exploitable. TMA³³ and β -catenin activation²⁶ scoring were performed as we previously described. Average *GLUL* and *ACE2* scores, *CTNNB1* mutational status and β -catenin activation scores for each HCC are provided in Supplementary Table 5. (h) Higher magnification from the indicated spots in (e) and (f).

mRNA expression data of five genes as follows: β -catenin activation score = $[(GLUL \times LGR5 \times O DAM) \div (VNN1 \times HAL)]^{26}$. Thus, we measured mRNA expression for these five genes by real-time PCR on mirror frozen samples from the same HCCs as those included in the TMA, applying our previously described method^{26,32,33}. GLUL and ACE2 protein expression were correlated with β -catenin activation scores (GLUL, $R = 0.69$, $p < 0.001$, $n = 41$; ACE2, $R = 0.51$, $p = 0.001$, $n = 38$). β -catenin activation scores ranged from -2 to 20 , median = 4 (Supplementary Table 5). As previously described²⁶, high scores (above the median), define perivenous-type HCCs. On average, GLUL and ACE2 proteins were respectively 4.0- and 2.6-fold higher in HCCs with high β -catenin activation scores (Fig. 1g). These results indicate that HCCs preserving a perivenous-type metabolic phenotype express higher level of ACE2 protein²⁶.

HCCs with mutated *CTNNB1* belong to the class of well-to-moderately differentiated tumors that preserve adult hepatocyte features²⁵. Thus, they are frequently cholestatic and contain pseudo-glandular structures with bile plugs, where hepatocytes are polarized and preserve the basal and apical poles³¹. Co-immunolabeling for ACE2 and ABCC2 (a.k.a. MRP2, a marker of the biliary pole in hepatocytes) in HCCs, detected ACE2 at the biliary pole and within the lumen of pseudo-glandular tumor structures and in slit-like bile canaliculi (Fig. 2a,b). By contrast, ACE2 was not detected at the basal hepatocyte pole, which was highlighted by the capillary endothelial cell marker CD34 (Fig. 2c). To quantify ACE2 protein expression at the biliary pole of HCC cells, we measured the fluorescence area for separate ACE2 and ABCC2 signals and for dual (ACE2 + ABCC2) staining in 96 TMA spots corresponding to 32 HCCs. To correct for differences in cell densities among HCCs, we plotted specific signal areas as the fraction of the DAPI area (i.e., nuclear staining) (Fig. 2d,e). Mean \pm SD ABCC2/DAPI or ACE2/DAPI ratios were: ABCC2/DAPI, $33 \pm 27\%$; ACE2/DAPI, $16 \pm 34\%$; (ACE2 + ABCC2)/DAPI, $3 \pm 6\%$. Of note, $19 \pm 25\%$ of all ACE2 expression (i.e., (ACE2 + ABCC2)/ACE2) was located at the biliary poles of HCC cells (Fig. 2d,e).

In tumors without *CTNNB1* mutations, only $8 \pm 9\%$ of all ACE2 was localized at the biliary poles. By contrast, in tumors with mutated *CTNNB1*, $31 \pm 27\%$ of all ACE2 was detected at the biliary poles (Fig. 2f) and the mean dual (ACE2 + ABCC2)/DAPI signal was 35 folds higher in HCCs carrying mutated than in tumors carrying wild-type *CTNNB1* (mean \pm SD: wild-type, 0.0018 ± 0.004 ; mutated, 0.063 ± 0.07 ; $p = 0.002$), thus confirming that HCCs carrying mutated *CTNNB1* are enriched in ACE2 expression and indicating that ACE2 is particularly associated with the biliary pole in tumor cells preserving polarized hepatocyte-like features. Adding robustness to these data, dual (ACE2 + ABCC2) expression was correlated with β -catenin activation scores (Spearman's $R = 0.58$, $n = 31$; $p = 0.0005$).

TMPRSS2 was also detected at the apical pole of some of the pseudo-glandular formations or within slit-like trabecular structures and in cell–cell borders (Supplementary Fig. 5). In contrast with ACE2, the signal for TMPRSS2 was mild in HCCs, suggesting low protein expression levels, which were unrelated to *CTNNB1* mutations. Neither ACE2 nor TMPRSS2 (not shown) were detected in myofibroblasts as suggested by dual ACE2 and ACTA2 staining (Supplementary Fig. 5).

In five non-tumor samples from patients undergoing resection of colon cancer metastases and with minimal inflammatory changes in the liver, ACE2 was co-detected with the sinusoidal endothelial cell marker CLEC4M (a.k.a. DC-SIGNR) (Fig. 3a,c,e) and the bile canaliculi marker ABCC2 (a.k.a. MRP2) (Fig. 3b,d,f). The presence of ACE2 within bile canaliculi is consistent with the facts that the extracellular part of ACE2 can be cleaved off the cell surface by ADAM17, thus shedding functional ACE2 fragments³⁴; and that ACE2 is an abundant component of the normal human bile proteome³⁵. Also, ACE2 was co-detected with CD34 in capillary vessels of the periportal vascular plexus (Fig. 3g). By contrast, ACE2 was not detected in CD68-positive sinusoidal cells (Kupffer cells, Fig. 3h) or ACTA2-positive vascular smooth muscle cells or myofibroblasts (Fig. 3i,j). As expected, the antibodies used detected high levels of ACE2 in the apical intestinal epithelium, Bowman's capsule and convoluted tubes in the kidney; in turn, TMPRSS2 was detected in the apical compartment of the epithelial lining of prostatic glands (Supplementary Fig. 5).

In summary, dual labeling of HCC and of non-neoplastic liver with cell-type specific antibodies showed ACE2 in the epithelial lining of bile ducts and in bile canaliculi, i.e., the biliary pole of normal and differentiated tumor hepatocytes. In non-neoplastic liver, CLEC4M-positive sinusoidal endothelial cells and CD34-positive capillary endothelial cells of the periportal vascular plexus also contain ACE2.

ACE2 and TMPRSS2 co-expression networks highlight metabolic functions typical of normal hepatocytes.

By Weighted Gene Correlation Network Analysis³⁶ comparing periportal-type ($n = 342$) and perivenous-type ($n = 225$) HCCs within the Désert's dataset ($n = 1133$), we found that ACE2 and TMPRSS2 were related through interacting metabolic functions (Fig. 4a), including detoxification, aminoacid catabolism, lipid metabolism, fatty acid oxidation and catabolism of organic compounds, which is probably related to the carboxypeptidase functions of ACE2, involved in the degradation of inflammatory polypeptides^{37,38} (Fig. 4b). These findings are in line with the above-described expression of ACE2 and TMPRSS2 in well-to-moderately differentiated HCCs preserving the metabolic programs of adult hepatocytes. Next, we specifically investigated the ACE2 co-expression network in HCCs and analyzed associated gene functions (Supplementary Tables 2, 3, 4). Not surprisingly, ACE2 was associated with hepatocyte-specific functions such as aminoacid metabolism, xenobiotic detoxification, fatty acid uptake and oxidation. High ACE2 expression was associated with low expression levels of oxidative stress markers and cytokine-mediated inflammatory signals (Supplementary Fig. 7a, b). These findings raise the hypothesis of a link between inflammation, ACE2 dysfunction and metabolic breakdown that may be relevant to the pathogenesis of COVID-19.




Figure 2. ACE2 is detected in the biliary pole of moderately-to-well-differentiated HCCs with trabecular or pseudo-glandular patterns. Combined immunoperoxidase and immunofluorescence analysis of a tissue microarray containing 41 HCCs and two normal liver controls, spotted in triplicates. Representative images are shown. Immunoperoxidase signal (brown) is counterstained with hematoxylin (blue). ACE2 appears in red by immunofluorescence, other markers in green and nuclei in blue (DAPI staining). (a), (b) ACE2 colocalizes with the apical hepatocyte marker ABCC2 (a.k.a. MRP2) (arrows). (c) Tumor capillary vessels are marked with CD34. Confocal digital images were acquired with a 40X objective. Images are Z-stacks of four 500 nm focusing steps. (d) Quantification of ACE2, ABCC2, dual (ABCC2 + ACE2) staining and the ratio of (ACE2 + ABCC2) × ACE2⁻¹, representing the fraction of ACE2 protein expression detected as dual (ACE2 + ABCC2) staining, i.e., the fraction of overlap of ACE2 with ABCC2. Values for individual TMA spots from 32 HCCs are expressed as the fraction of DAPI staining of nuclei, to correct for natural variations in cell density in each spot. Means ± 95% confidence intervals are shown for each condition. The statistical significance between groups was calculated with Kruskal–Wallis test ($p < 0.0001$), followed by the post-hoc Dunn's test as indicated. (e) Sample scan from a TMA spot showing examples for the different signals quantified in (d). (f) The fraction of overlapping (ACE2 + ABCC2) over total ACE2 signal (i.e., HCC cells expressing ACE2 at the biliary pole), is higher in HCCs carrying CTNNB1 mutations. Each data point represents the mean of two to three cores for each tumor. Statistical significance calculated by Mann–Whitney U test.




Figure 3. ACE2 is detected in sinusoidal endothelial cells, bile ducts and capillaries of the periportal plexus in non-tumor livers. Co-immunostaining for ACE2 and the indicated markers in three non-tumor livers from patients undergoing resection of colon cancer metastasis. Representative images are shown. ACE2 appears in *red* by immunofluorescence, other markers in *green* and nuclei in *blue* (DAPI staining). (a), (b) Low power views (X5 magnification) show ACE2 in a bile duct (BD) and in a zone with mild inflammatory infiltration (arrow) and dystrophic bile ducts (BDs). The sinusoidal endothelial cell marker CLEC4M (a.k.a. DC-SIGNR) and the bile canaliculi marker ABCC2 (a.k.a. MRP2) show lobular staining at this magnification. Pt, portal tract. (c), (d) At X30 magnification, ACE is detected in sinusoidal endothelial cells, which can be identified by comparing CLEC4M (c) and ABCC2 (d) staining. Digital images were acquired with a microscope scanner and a X40 objective and exported at the indicated magnifications (Nanozoomer, Hamamatsu Photonics). (e), (f) Confocal scans of whole tissue sections as Z-stacks of 4 X 500 nm focusing steps at X40 (e) and X143 (f). ACE2 is detected in CLEC4M-positive sinusoidal endothelial cells (e) and within ABCC2-positive bile canaliculi (f). ACE2-positive bile ducts (BDs) are seen in (e). (g) At 28X magnification, ACE2 is sparsely detected in CD34-positive endothelial cells of the periportal vascular plexus (arrows). (h) At 24X magnification, no evidence of ACE2 detection in CD68-positive Kupffer cells. (i), (j) No evidence of ACE2 detection in vascular smooth muscle (i, 10X magnification) or in ACTA2 (a.k.a. alpha smooth muscle actin)-positive cells within portal tract stroma (j, 20X magnification). ACE2-positive cells within the portal tract are ACTA2 negative (arrows).



a ACE2- and TMPRSS2-related Metabolic Networks**b**

Figure 4. (a) Connections between the *ACE2* and the *TMPRSS2* expression networks in the Désert's meta-dataset²⁶, in non-proliferative-moderately-to-well-differentiated, periportal-type and perivenous-type HCCs²⁴. The co-expression network was identified by Weighted Gene Correlation Network Analysis and the WGCNA³⁶ R package, followed by visualization with Cytoscape⁴⁹. Genes co-expressed with *ACE2*, light-blue nodes with black borders and black links; genes co-expressed with *TMPRSS2*, white nodes with red borders and black links; genes co-expressed with both *ACE2* and *TMPRSS2*, light-blue nodes with red borders and blue links. Link thickness is proportional to the correlation coefficient between a given node and *ACE2* or *TMPRSS2*. (b) Functional analysis and gene ontology enrichment of the gene co-expression network shown in *b* are visualized with Express Analysis from Metascape⁵⁰. Gene ontology (GO) terms, families and *P* values are indicated.

Discussion

In this work, we show that *ACE2* and *TMPRSS2* mRNAs and proteins are detected at higher levels in well-to-moderately differentiated HCCs than in poorly differentiated tumors. In particular, *ACE2* is detected at the biliary pole in tumors preserving hepatocyte polarization. By contrast, in non-tumor livers, *ACE2* is detected not only in the epithelial lining of bile ducts and within hepatocyte's bile canaliculi, but also in the CLEC4M-positive sinusoidal endothelium and the CD34-positive capillary vessels of the periportal plexus. *TMPRSS2*, in turn, is not detected in normal liver, but is detected at the biliary pole in well-to-moderately differentiated HCCs, which is consistent with the functional association of *ACE2* and *TMPRSS2* through periportal and perivenous metabolic

networks. Of note, high-resolution 500-nm optical sections revealed ACE2 within hepatocyte's bile canaliculi in histologically normal liver. This finding agrees with the high content of N-glycosylated, lectin-binding ACE2 in the normal human bile proteome³⁵ and with the role of ACE2 in aminoacid uptake in the gut and in the regulation of the splanchnic blood flow³⁷.

In HCCs carrying activating β -catenin (*CTNNB1*) mutations, *ACE2* DNA is hypomethylated, and *ACE2* mRNA expression upregulated. Conversely, *TMPRSS2* mRNA is lower in HCCs carrying mutated *CTNNB1* and its DNA hypermethylated. This finding agrees with the fact that only *ACE2* (and *DPP4*, but not *TMPRSS2*) contain TCF/LEF-1 binding sites that are predicted to respond to β -catenin transcriptional activation. Neither *ACE2*, nor *DPP4* or *TMPRSS2* are associated to *TERT* or *TP53* gene mutations. On the contrary, HCCs containing mutated *TP53* show relatively lower levels of *TMPRSS2* (Supplementary Fig. 3D). This association does not necessarily imply a direct regulation of *TMPRSS2* by *TP53*, but may be coincidental. In fact, well-differentiated, periportal-type HCCs express the highest levels of *TMPRSS2* and, as we previously showed, have the lowest prevalence of *TP53* mutations²⁶. Nonetheless, the relationships of *ACE2* and *TMPRSS2* with histological, transcriptomic and genomic HCC subclasses converge to demonstrate that tumors preserving hepatocyte-like features, such as hepatocyte trabeculae with bile canaliculi and/or pseudo-glandular structures with an apical biliary pole, express higher levels of the SARS-CoV-2 receptor and co-receptor couple.

The above findings agree with further observations in this work: the *ACE2* co-expression network included liver-enriched genes involved in hepatocyte-specific functions, such as aminoacid metabolism (*GNMT*), xenobiotic detoxification (*CYP3A4*), fatty acid uptake, bile acid rejugation (*SLC27A5*), enterohepatic circulation of bile acids and cholesterol homeostasis (*SLC10A1*). *ACE2* was also co-expressed with *SIRT1* and *CD36* and the fatty acid oxidation enzymes *ACADL*, *EHHADH*, *ACADM* and *ECI2*, and alternative glucose metabolism pathways (*CRYL1*), as well as enzymes involved in gluconeogenesis (*PCK2*). This network is in line with the role of *ACE2* as a regulator of fatty acid uptake in hepatocytes through the angiotensin₁₋₇-MAS1-SIRTUIN1-CD36 axis³⁹. Indeed, *ACE2* knock-out mice show low levels of peripheral lipid uptake, but high hepatocyte uptake of triglycerides, resulting in steatosis, lipid peroxidation, oxidative stress and inflammation³⁹. In turn, the induction of oxidative stress by *ACE2* deficiency may be related to its effects on glucose and lipid metabolism because the *ACE2*/Ang₁₋₇/MAS axis increases glucose uptake, decreasing insulin resistance. Thus, *ACE2* knock-out mice exhibit high oxidative stress, whereas exposure to Ang₁₋₇ reduces oxidative stress in liver cells through insulin signaling⁴⁰. Taken together, this body of evidence matches the metabolic landscape of HCCs carrying activating *CTNNB1* mutations. These tumors oxidize fatty acids as a source of energy to feed the oxidative phosphorylation pathway⁴¹, but resist to oxidative stress⁴² and suppress inflammation⁴³.

ACE2 expression was related to gene functions that smother inflammation. Indeed, *ACE2* was related to low levels of the inflammation-related transcripts *BIRC3*, *MSN*, *MMP9*, *LTB*, *TNFRSF4*, *IL4R*, *CCL20* and *IL32*, among others (Supplementary Table 2). *ACE2* exerts anti-inflammatory effects through carboxyterminal cleavage of vasoactive polypeptides, such as Apelin-13, which induces vasodilation, and des-arg9-bradykinin, a neutrophil chemoattractant⁴⁴. In turn, deletion of *ACE2* leads to tissue injury and oxidative stress, through upregulation of the *AT1* receptor and inflammatory cytokines like *IL1 β* , *IL6*, *IL17*, *RANTES*, *ICAM1*, *TNF α* , *TNFRSF1A* and downregulation of the anti-inflammatory cytokine *IL10*⁴⁵. This picture is surprisingly similar to that seen in the spectrum going from immune dysregulation to macrophage activation syndrome in moderate-to-severe COVID-19^{4,46}.

The anti-inflammatory role of *ACE2* goes well with its up-regulation in response to liver injury, such as bile-duct ligation⁴⁷ and with the evidence that *ACE2* produced by hepatocytes limits fibrogenesis through degradation of AngII to Ang₁₋₇³⁷. In human liver cirrhosis, *ACE2* protein is increased by > 90 folds in hepatocytes. In vitro, hypoxia increases *ACE2* activity in hepatocytes, enhancing acetylcholine-induced vasodilatation³⁸. As hypoxia activates Wnt/ β -catenin signaling, it would be interesting to investigate whether *ACE2* expression in perivenous hepatocytes depends on β -catenin^{34,48}.

This body of matching data suggests that *ACE2* may regulate energy metabolism, protecting against oxidative stress and inflammation. As both *TMPRSS2* and *ACE2* are functionally connected through metabolic pathways in the liver, it may be reasonable to hypothesize that *ACE2* depletion resulting from SARS-CoV-2 infection¹⁸ may contribute to metabolic dysfunction and inflammation. Our results point to the relevance of further studies on the signaling pathways and pathological contexts leading to cell surface *ACE2* availability and to the possible impact of viral infection on the disruption of the *ACE2* metabolic network.

Materials and methods

Patients, samples and datasets. *Human hepatocellular carcinoma (HCC)*: immunohistochemistry was performed on a tissue microarray (TMA) built from formalin-fixed-paraffin-embedded (FFPE) routine tissue blocks of 41 HCC cases and two histologically normal liver controls, for which the exon 3 of β -catenin (*CTNNB1*) had been Sanger-sequenced, as we previously described²⁶. In addition, three formalin-fixed, paraffin-embedded non-tumor liver tissue blocks from patients undergoing resection of liver metastases from extra-hepatic cancers were added to the immunohistochemistry analysis. To calculate β -catenin activation scores based on the mRNA expression of *GLUL*, *LGR5*, *ODAM*, *VNN1* and *HAL*, we retrieved real-time PCR mRNA expression data from our previously published work²⁶ corresponding to frozen fragments of the 41 tumors arrayed in the TMA. Quality control matching of frozen and FFPE fragments has been previously described in an 80 HCC dataset including the 41-tumor subset^{32,33}. Tissue samples and patient data were collected and anonymized after obtaining written informed consent from the patients. De-identification was performed in accordance with the Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule. The study was approved by INSERM's Institutional Advisory Board (approval number 19–630). Research involving human research participants has been performed in accordance with the Declaration of Helsinki. All experiments were performed in accordance with

relevant guidelines and regulations. Two different immunohistochemical methods were used to detect primary antibodies: peroxidase-labeled secondary antibodies, revealed by a chromogenic substrate or multiplex immunofluorescence followed by analysis with a confocal slide scanner. The Désert's microarray meta-dataset composed of 1133 human HCCs was previously described²⁶. In this dataset, HCCs expressing a β -catenin-activated transcriptomic program were identified with a 5-gene signature composed of *GLUL*, *LGR5*, *ODAM*, *VNN1* and *HAL*, which predicts activating *CTNNB1* mutations with high sensitivity (0.86–0.91) and specificity (0.83–1.0)²⁶. β -catenin pathway activation was confirmed with an independent 23-gene signature²⁷. The publicly available TCGA dataset was composed of 370 HCCs and 47 matching non-tumor samples. RNA sequencing, mutation and methylation data were extracted as described²⁶, using the *TCGAbiolinks* R package. Raw mRNA expression was median-normalized (*DESeq* R package). DNA methylation was quantile-normalized (*preprocessCore* R package); probes with B-value over 0.8 or under 0.2 were respectively considered as hypermethylated or hypomethylated. The R-package *Limma* was used to identify differential methylation.

See *Supplementary Information* for a detailed description of immunohistochemical methods and statistical analyses and Supplementary Table 6 for primary, secondary antibodies, fluorochromes used, epitope unmasking and incubation conditions.

Data availability

Datasets analyzed in this study are available at The Cancer Genome Atlas or at the Gene Expression Omnibus databases. Accession numbers and standard, publicly available R packages used are provided in the main text and supplementary files. The procedures applied for merging nine publicly available transcriptomic datasets into a meta-dataset totaling 1133 hepatocellular carcinomas have been previously published²⁶. A filtered, normalized and batch-effect-corrected user-friendly version of this meta-dataset is available from the corresponding author upon reasonable request.

Received: 9 August 2021; Accepted: 8 December 2021

Published online: 03 February 2022

References

- Guan, W.-J. *et al.* Clinical characteristics of coronavirus disease 2019 in China. *N. Engl. J. Med.* **382**, 1708–1720. <https://doi.org/10.1056/NEJMoa2002032> (2020).
- Bhatraju, P. K. *et al.* Covid-19 in critically ill patients in the seattle region—case series. *N. Engl. J. Med.* <https://doi.org/10.1056/NEJMoa2004500> (2020).
- Grasselli, G. *et al.* Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. *JAMA* **323**, 1574–1581. <https://doi.org/10.1001/jama.2020.5394> (2020).
- Giamarellos-Bourboulis, E. J. *et al.* Complex immune dysregulation in COVID-19 patients with severe respiratory failure. *Cell Host Microbe* <https://doi.org/10.1016/j.chom.2020.04.009> (2020).
- Zhou, F. *et al.* Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* **395**, 1054–1062. [https://doi.org/10.1016/S0140-6736\(20\)30566-3](https://doi.org/10.1016/S0140-6736(20)30566-3) (2020).
- Wu, C. *et al.* Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. *JAMA Int. Med.* <https://doi.org/10.1001/jamainternmed.2020.0994> (2020).
- Mantovani, A., Beatrice, G. & Dalbeni, A. Coronavirus disease 2019 and prevalence of chronic liver disease: a meta-analysis. *Liver Int* <https://doi.org/10.1111/liv.14465> (2020).
- Mao, R. *et al.* Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. *Lancet Gastroenterol Hepatol* [https://doi.org/10.1016/S2468-1253\(20\)30126-6](https://doi.org/10.1016/S2468-1253(20)30126-6) (2020).
- Zhang, C., Shi, L. & Wang, F. S. Liver injury in COVID-19: management and challenges. *Lancet Gastroenterol. Hepatol.* **5**, 428–430. [https://doi.org/10.1016/S2468-1253\(20\)30057-1](https://doi.org/10.1016/S2468-1253(20)30057-1) (2020).
- Xie, H. *et al.* Clinical characteristics of non-ICU hospitalized patients with coronavirus disease 2019 and liver injury: A retrospective study. *Liver Int* <https://doi.org/10.1111/liv.14449> (2020).
- Cai, Q. *et al.* COVID-19: abnormal liver function tests. *J. Hepatol.* <https://doi.org/10.1016/j.jhep.2020.04.006> (2020).
- Xu, Z. *et al.* Pathological findings of COVID-19 associated with acute respiratory distress syndrome. *Lancet Respir Med* **8**, 420–422. [https://doi.org/10.1016/S2213-2600\(20\)30076-X](https://doi.org/10.1016/S2213-2600(20)30076-X) (2020).
- Tian, S. *et al.* Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies. *Modern Pathol* <https://doi.org/10.1038/s41379-020-0536-x> (2020).
- Wang, Y. *et al.* SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19. *J. Hepatol.* <https://doi.org/10.1016/j.jhep.2020.05.002> (2020).
- Chen, W. *et al.* Detectable 2019-nCoV viral RNA in blood is a strong indicator for the further clinical severity. *Emerg. Microbes Infections* **9**, 469–473. <https://doi.org/10.1080/22221751.2020.1732837> (2020).
- Puelles, V. G. *et al.* Multiorgan and renal tropism of SARS-CoV-2. *N Engl J Med* <https://doi.org/10.1056/NEJMc2011400> (2020).
- Su, H. *et al.* Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. *Kidney Int* <https://doi.org/10.1016/j.kint.2020.04.003> (2020).
- Hoffmann, M. *et al.* SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. *Cell* **181**, 271–280. <https://doi.org/10.1016/j.cell.2020.02.052> (2020).
- Zhou, P. *et al.* A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* **579**, 270–273. <https://doi.org/10.1038/s41586-020-2012-7> (2020).
- Nie, J. *et al.* Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2. *Emerg. Microbes Infections* **9**, 680–686. <https://doi.org/10.1080/22221751.2020.1743767> (2020).
- Ye, G. *et al.* The association of renin-angiotensin system genes with the progression of hepatocellular carcinoma. *Biochem. Biophys. Res. Commun.* **459**, 18–23 (2015).
- Dai, Y. J. *et al.* A profiling analysis on the receptor ACE2 expression reveals the potential risk of different type of cancers vulnerable to SARS-CoV-2 infection. *Ann Transl Med* **8**, 61 (2020).
- Fu, J. *et al.* Expressions and significances of the angiotensin-converting enzyme 2 gene, the receptor of SARS-CoV-2 for COVID-19. *Mol. Biol. Rep.* <https://doi.org/10.1007/s11033-020-05478-4> (2020).
- Desert, R., Nieto, N. & Musso, O. Dimensions of hepatocellular carcinoma phenotypic diversity. *World J. Gastroenterol.* **24**, 4536–4547. <https://doi.org/10.3748/wjg.v24.i40.4536> (2018).

25. Zucman-Rossi, J., Villanueva, A., Nault, J. C. & Llovet, J. M. Genetic landscape and biomarkers of hepatocellular carcinoma. *Gastroenterology* **149**, 1226–1239. <https://doi.org/10.1053/j.gastro.2015.05.061> (2015).
26. Desert, R. *et al.* Human hepatocellular carcinomas with a periportal phenotype have the lowest potential for early recurrence after curative resection. *Hepatology* **66**, 1502–1518. <https://doi.org/10.1002/hep.29254> (2017).
27. Abitbol, S. *et al.* AXIN deficiency in human and mouse hepatocytes induces hepatocellular carcinoma in the absence of beta-catenin activation. *J. Hepatol.* **68**, 1203–1213. <https://doi.org/10.1016/j.jhep.2017.12.018> (2018).
28. Guichard, C. *et al.* Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. *Nat. Genet.* **44**, 694–698. <https://doi.org/10.1038/ng.2256> (2012).
29. Hoshida, Y. *et al.* Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. *Can. Res.* **69**, 7385–7392. <https://doi.org/10.1158/0008-5472.CAN-09-1089> (2009).
30. Boyault, S. *et al.* Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. *Hepatology* **45**, 42–52. <https://doi.org/10.1002/hep.21467> (2007).
31. Calderaro, J. *et al.* Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification. *J. Hepatol.* **67**, 727–738. <https://doi.org/10.1016/j.jhep.2017.05.014> (2017).
32. Mebarki, S. *et al.* De novo HAPLN1 expression hallmarks Wnt-induced stem cell and fibrogenic networks leading to aggressive human hepatocellular carcinomas. *Oncotarget* **7**, 39026–39043. <https://doi.org/10.18632/oncotarget.9346> (2016).
33. Desert, R. *et al.* “Fibrous nests” in human hepatocellular carcinoma express a Wnt-induced gene signature associated with poor clinical outcome. *Int. J. Biochem. Cell Biol.* **81**(Pt A), 195–207. <https://doi.org/10.1016/j.biocel.2016.08.017> (2016).
34. Joshi, S., Wollenzien, H., Leclerc, E. & Jarajapu, Y. P. Hypoxic regulation of angiotensin-converting enzyme 2 and Mas receptor in human CD34+ cells. *J. Cell. Physiol.* **234**, 20420–20431. <https://doi.org/10.1002/jcp.28643> (2019).
35. Kristiansen, T. Z. *et al.* A proteomic analysis of human bile. *Mol. Cell. Proteomics* **3**, 715–728. <https://doi.org/10.1074/mcp.M400015-MCP200> (2004).
36. Langfelder, P. & Horvath, S. WGCNA: an R package for weighted correlation network analysis. *BMC Bioinf.* **9**, 559. <https://doi.org/10.1186/1471-2105-9-559> (2008).
37. Osterreicher, C. H. *et al.* Angiotensin-converting-enzyme 2 inhibits liver fibrosis in mice. *Hepatology* **50**, 929–938. <https://doi.org/10.1002/hep.23104> (2009).
38. Paizis, G. *et al.* Chronic liver injury in rats and humans upregulates the novel enzyme angiotensin converting enzyme 2. *Gut* **54**, 1790–1796. <https://doi.org/10.1136/gut.2004.062398> (2005).
39. Nunes-Souza, V. *et al.* CD36/Sirtuin 1 axis impairment contributes to hepatic steatosis in ACE2-deficient mice. *Oxid. Med. Cell Longev.* **2016**, 6487509. <https://doi.org/10.1155/2016/6487509> (2016).
40. Cao, X., Yang, F. Y., Xin, Z., Xie, R. R. & Yang, J. K. The ACE2/Ang-(1–7)/Mas axis can inhibit hepatic insulin resistance. *Mol. Cell Endocrinol.* **393**, 30–38. <https://doi.org/10.1016/j.mce.2014.05.024> (2014).
41. Senni, N. *et al.* beta-catenin-activated hepatocellular carcinomas are addicted to fatty acids. *Gut* <https://doi.org/10.1136/gutjnl-2017-315448> (2018).
42. Charawi, S. *et al.* LKB1 signaling is activated in CTNNB1-mutated HCC and positively regulates β -catenin-dependent CTNNB1-mutated HCC. *J. Pathol.* **247**, 435–443. <https://doi.org/10.1002/path.5202> (2019).
43. Sia, D. *et al.* Identification of an immune-specific class of hepatocellular carcinoma based on molecular features. *Gastroenterology* **153**, 812–826. <https://doi.org/10.1053/j.gastro.2017.06.007> (2017).
44. Arendse, L. B. *et al.* Novel therapeutic approaches targeting the renin-angiotensin system and associated peptides in hypertension and heart failure. *Pharmacol. Rev.* **71**, 539–570. <https://doi.org/10.1124/pr.118.017129> (2019).
45. Jin, H.-Y. *et al.* Deletion of angiotensin-converting enzyme 2 exacerbates renal inflammation and injury in apolipoprotein E-deficient mice through modulation of the nephrin and TNF- α -TNFRSF1A signaling. *J. Transl. Med.* **13**, 255. <https://doi.org/10.1186/s12967-015-0616-8> (2015).
46. Pedersen, S. F. & Ho, Y.-C. SARS-CoV-2: a storm is raging. *J. Clin. Invest.* **130**, 2202–2205. <https://doi.org/10.1172/jci137647> (2020).
47. Paizis, G. *et al.* Up-regulation of components of the renin-angiotensin system in the bile duct-ligated rat liver. *Gastroenterology* **123**, 1667–1676. <https://doi.org/10.1053/gast.2002.36561> (2002).
48. Zhan, L. *et al.* Hypoxic postconditioning activates the Wnt/ β -catenin pathway and protects against transient global cerebral ischemia through Dkk1 inhibition and GSK-3 β inactivation. *FASEB J.* **33**, 9291–9307. <https://doi.org/10.1096/fj.201802633R> (2019).
49. Shannon, P. *et al.* Cytoscape: a software environment for integrated models of biomolecular interaction networks. *Genome Res.* **13**, 2498–2504. <https://doi.org/10.1101/gr.1239303> (2003).
50. Zhou, Y. *et al.* Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. *Nat. Commun.* **10**, 1523. <https://doi.org/10.1038/s41467-019-09234-6> (2019).

Acknowledgements

We thank Caroline Aninat, Latifa Bousarghin, Pierre-Jean Ferron and Olivier Loréal for insightful discussions; Michèle Le Guennec, Patricia Jouas, Adina Pascu and Thomas Poussou for logistics and administrative support.

Author contributions

Study design, O.M., L.D., L.C., A.C., B.C.; meta-datasets merge and pretreatment, L.D., R.D.; database search, L.D., L.C., C.L., O.M.; anatomic pathology analysis, B.T., L.C., O.M.; immunohistochemistry, G.G.; statistics, L.D., L.C., O.M.; image analysis, L.C., N.M., O.M.; data analysis, L.D., L.C., O.M.; manuscript preparation, L.D., L.C., O.M.; manuscript editing, all authors.

Funding

Inserm; Univ Rennes 1; Ministère de l’Enseignement Supérieur; Institut National du Cancer, grant # INCA_12688; Ligue Nationale Contre le Cancer 2018, Comités d’Ille-et-Vilaine et Vendée.

Competing interests

The authors declare no competing interests.

Additional information

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1038/s41598-021-03710-0>.

Correspondence and requests for materials should be addressed to O.M.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2022